KCA
MBX

KVP Capital Advisors’s MBX Biosciences MBX Stock Holding History

KVP Capital Advisors’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.71M Hold
121,524
– – 4.92% 7
2026
Q1 		$3.63M Hold
121,524
– – 2.71% 14
2025
Q4 		$3.83M Buy
+121,524
New +$2.95M 3.71% 10

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

KVP Capital Advisors's MBX Position: Q2 2026 in Review

KVP Capital Advisors held its MBX Biosciences (MBX) position steady in Q2 2026 at 121,524 shares worth $6.71M. The position accounts for 4.92% of the portfolio, ranked #7.

KVP Capital Advisors first reported a position in MBX in Q4 2025 and has held it in 3 quarters since. 173 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • KVP Capital Advisors held 121,524 shares of MBX Biosciences worth $6.71M as of Q2 2026.
  • KVP Capital Advisors left its MBX Biosciences share count unchanged in Q2 2026.
  • MBX Biosciences made up 4.92% of KVP Capital Advisors's portfolio in Q2 2026, its #7 holding.
  • KVP Capital Advisors first reported a position in MBX Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 173 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on KVP Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.